If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Agreement Signed for Activated Cell Therapy Product NEWTON, Mass., PRINCETON, N.J., and DUBLIN, Ohio, Dec. 11, 1996 -- Cellcor, a wholly owned subsidiary of CYTOGEN Corporation (Nasdaq: CYTO) and Neoprobe Corporation (Nasdaq: NEOP) announced today the signing of an agreement whereby Neoprobe will use Cellcor's cell processing and development facility and established processes to manufacture Neoprobe's activated cell therapy (ACT) product called RIGS/ACT(TM), for the treatment of metastatic colorectal cancer. The Letter of Intent was previously announced by the companies in June, 1996. Cellcor will receive an up-front fee and will be recording contract revenue on a per patient basis over the next few years. Neoprobe retains the exclusive right to all clinical results and all processes and procedures currently used to manufacture the RIGS/ACT product. Under the terms of the agreement, Neoprobe will use Cellcor's cell processing infrastructure for the clinical development of its RIGS/ACT product. Neoprobe is beginning a Phase II trial for RIGS/ACT as a treatment for metastatic colorectal cancer and is conducting a Phase I study for the treatment of breast cancer. Cellcor, through the development of its autologous cellular therapy, known as autolymphocyte therapy (ALT), has an established Good Manufacturing Practices (GMP) manufacturing facility in Newton, Massachusetts. Cellcor's GMP facility, with its proven expertise in patient-specific autologous lymphocyte processing in a high volume commercial setting, is the only one of its kind on the East coast of the United States. David Bupp, President of Neoprobe, stated, "Results of the RIGS/ACT clinical trials have shown encouraging patient response to the treatment thus far. By accessing Cellcor's established capabilities in the area of cell processing and the GMP facility, we can accelerate the clinical development of our RIGS/ACT product, while ensuring quality, in a very cost effective way." "It is extremely gratifying to witness the achievement of another milestone which supports CYTOGEN's business strategy of bringing to market our core capabilities through partnerships such as the Cellcor and Neoprobe collaboration," said Thomas J. McKearn, CYTOGEN's Chairman of the Board, President and Chief Executive Officer. Cellular therapies, such as ACT and ALT treat disease by using a patient's own lymphocytes to enhance the patient's immune response to cancer. Neoprobe's RIGS/ACT is used for patients who have surgery as part of their treatment. It is unique among cellular therapies in that during a patient's surgery, Neoprobe's RIGS(R) system is used to identify otherwise indistinguishable lymph nodes that contain an unusual number of the "helper" lymphocytes. The lymph nodes are removed, and the lymphocytes are grown outside the body. Within 10 to 14 days, more than one billion helper cells are infused back into the patient, with minimal side effects, to treat the disease. The infusion is given in the hospital before the patient goes home after surgery or a few days later in an outpatient setting. Cellcor's lead product has been developed as a treatment for metastatic renal cell carcinoma (mRCC), or advanced kidney cancer and utilizes the Company's proprietary T cell technology. ALT involves the ex vivo stimulation of lymphocytes from a patient's own blood which are readministered into the patient to augment the patient's own immune system and enhance his response to foreign antigens such as cancer or infectious disease. This process is conducted on an outpatient basis. In published scientific reports, ALT has demonstrated the potential to prolong survival in certain patients with mRCC and is extremely well-tolerated. Neoprobe Corporation is dedicated to improving the diagnosis and treatment of cancer. The Company is developing and commercializing products worldwide that are based on its proprietary RIGS technology. The RIGS system combines small, hand-held radiation detectors and injectable radiolabeled disease- targeting agents. These two components working together are designed to provide surgeons with immediate information about the location of diseased tissue during surgery. Neoprobe is developing RIGS surgical detection products for many cancer types and RIGS/ACT cellular therapy for metastatic colorectal cancer. Neoprobe's products are designed to improve the standard of care for cancer patients. Cellcor, Inc., CYTOGEN's wholly-owned subsidiary, is an immunotherapy company focused on the development, manufacturing and commercialization of products to treat cancer and infectious diseases using a patient's own living cells. CYTOGEN Corporation is a biopharmaceutical company engaged in the development, manufacture and commercialization of products for the targeted delivery of diagnostic and therapeutic substances to molecular and cellular sites of disease. According to the Biotechnology Industry Organization (BIO), there are over 1300 biopharmaceutical firms in the United States. CYTOGEN is one of eight to have received FDA licensure for more than one pharmaceutical product. CYTOGEN has demonstrated its ability to develop novel technology from early discovery through clinical development, regulatory approval and commercial-scale biologic manufacturing. Except for the historical information contained herein, the matters discussed in this press release contain forward looking statements that involve risks and uncertainties detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 1995.
|
